A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
Phase 1
4–12
6 sites in CA, FL, LA +2
About this study
This Phase 1 study is testing Budesonide in people with asthma. The primary outcome being measured is Maximum observed plasma concentration (Cmax).
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
budesonide, Respiratory System Agent (Adrenergic beta2-Agonists)
oral (Delayed Release Oral Capsule)
Primary: Maximum observed plasma concentration (Cmax)
Secondary: Apparent total body clearance (CL/F), Number of participants with adverse events, Terminal elimination half-life (t½λz), Time to reach peak or maximum observed concentration or response following drug administration (tmax)
Respiratory